



an Open Access Journal by MDPI

The Contribution of Astrocytes to Human Neurodegenerative Diseases

Guest Editors:

Prof. Dr. Rickie Patani

Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK

Dr. Ben Clarke

Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK

Deadline for manuscript submissions:

closed (15 May 2022)

Message from the Guest Editors

Neurodegeneration occurs in several devastating and incurable diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis. The precise mechanisms by which neurons become dysfunctional and ultimately degenerate remain largely unresolved, but there is an increasing recognition for the role of astrocytes in disease pathomechanisms. Astrocytes fulfil multiple supportive roles in aiding neuronal function in the central nervous system (CNS) but have been found to become dysfunctional in several neurodegenerative diseases, sometimes coinciding with the acquisition of neurotoxic immune phenotypes. This Special Issue focuses specifically on novel insights concerning how astrocytes contribute to the molecular and cellular phases of human neurological diseases. Original manuscripts and/or reviews dealing with these issues are most welcome from outstanding experts on the topic.



mdpi.com/si/84866

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)